During the last few years, several new drugs have been introduced for treatment of patients with multiple myeloma, which have significantly improved treatment outcome. All of these novel substances differ at least in part in their mode of action from similar drugs of the same drug class, or are representatives of new drugs classes, and as such present with very specific side effect profiles. In this review, we summarize these adverse events, provide information on their prevention, and give practical guidance for monitoring of patients and for management of adverse events.Leukemia accepted article preview online, 18 December 2017. doi:10.1038/leu.2017.353.

中文翻译：

---

多发性骨髓瘤新药不良事件的预防和管理：欧洲骨髓瘤网络共识。


在过去的几年中，多种新药被引入用于治疗多发性骨髓瘤患者，显着改善了治疗效果。所有这些新物质的作用方式至少部分不同于同一药物类别的类似药物，或者是新药物类别的代表，因此具有非常特殊的副作用特征。在这篇综述中，我们总结了这些不良事件，提供了有关其预防的信息，并为患者监测和不良事件管理提供了实用指导。白血病在线接受文章预览，2017年12月18日。doi:10.1038/leu.2017.353。